Výsledky vyhledávání - "Charles A. Koller"

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Autor: Susan Lerner, Jan A. Burger, Xuemei Wang, Michael J. Keating, Alessandra Ferrajoli, Susan O'Brien, Stefan Faderl, William G. Wierda, Hagop M. Kantarjian, Charles A. Koller, Xavier Badoux

Publikováno v: Blood. 117:3016-3024

Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e63497662926ba6e1f44253d64ac5f51
https://doi.org/10.1182/blood-2010-08-304683

Zobrazit plný text záznamu

Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

Autor: Javier Loscertales, Michael J. Keating, Deborah A. Thomas, Hagop M. Kantarjian, Francis J. Giles, Jorge E. Cortes, Susan O'Brien, Charles A. Koller

Publikováno v: Cancer. 92:2016-2022

BACKGROUND Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the curr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07ae9f2eff8b7ab73327394bee846b67
https://doi.org/10.1002/1097-0142(20011015)92:8<2016::aid-cncr1539>3.0.co

Zobrazit plný text záznamu

High-dose chemotherapy in high-risk myelodysplastic syndrome

Autor: Charles A. Koller, Elihu H. Estey, Deborah A. Thomas, Hagop Kantarjian, Jorge Cortes, Miloslav Beran, Stefan Faderl, Simona Despa, Francis J. Giles, Susan O'Brien, Yu Shen

Publikováno v: Cancer. 92:1999-2015

BACKGROUND Antileukemic chemotherapy has been used for two decades to treat high-risk myelodysplastic syndrome (refractory anemia with excess of blasts [RAEB] and RAEB in transformation into acute leukemia [RAEB-t]) patients. Because the results of s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43c738521a39581cc1aa87698d9ceb79
https://doi.org/10.1002/1097-0142(20011015)92:8<1999::aid-cncr1538>3.0.co

Zobrazit plný text záznamu

A Phase I trial of weekly lomustine in patients with advanced cancer

Autor: Carl Plager, C R N Carolyn Gorski, Nicholas E. Papadopoulos, Charles A. Koller, Sewa S. Legha, Robert S. Benjamin

Publikováno v: Cancer. 73:236-239

Background. Lomustine is a commercially available chloroethyl nitrosourea compound whose antitumor activity in vitro and in animal tumor models exceeds its activity in humans. Part of the poor clinical performance of this drug may be explained by dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebba579afac82115a3d9984f45949afe
https://doi.org/10.1002/1097-0142(19940101)73:1<236::aid-cncr2820730140>3.0.co

Zobrazit plný text záznamu

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Autor: Rajyalakshmi Luthra, Jan A. Burger, Pramoda Challagundla, Sergernne York, Sherry Pierce, Deborah A. Thomas, Jeffrey L. Jorgensen, Stefan Faderl, Mark Brandt, Susan O'Brien, Alessandra Ferrajoli, Charles A. Koller, Farhad Ravandi, Michael J. Keating, Hagop M. Kantarjian

We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m2 given IV over 2 hours daily for 5 days was followed ∼

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d0dd817c22f2e33fe33810e664c2801
https://europepmc.org/articles/PMC4081440/

Zobrazit plný text záznamu

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Autor: William G. Wierda, Susan O'Brien, Michael J. Keating, Sameer A. Parikh, Susan Lerner, Zeev Estrov, Alessandra Ferrajoli, Xavier Badoux, Stefan Faderl, Jan A. Burger, Charles A. Koller, Xuemei Wang

Publikováno v: Blood. 118(8)

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae006b22fe15fdb43a71f304498b0da8
https://pubmed.ncbi.nlm.nih.gov/21750315

Zobrazit plný text záznamu

Determination of Plicamycin in Plasma by Radioimmunoassay

Autor: Kang Fang, N. S. Brown, Dah Hsi Ho, Wendy Covington, Charles A. Koller, Juan Ru Lin

Publikováno v: Therapeutic Drug Monitoring. 14:255-260

This article describes a method for the determination of plicamycin in plasma by radioimmunoassay. The anti-plicamycin antibody was produced against a plicamycin-bovine serum albumin conjugate prepared by using diazotized p-aminobenzoic acid as a cro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ef19b996f86868c01d3d212cfb4b84
https://doi.org/10.1097/00007691-199206000-00013

Zobrazit plný text záznamu

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Autor: Constantine S. Tam, Susan O'Brien, Charles A. Koller, Elias Jabbour, William G. Wierda, Dan Jones, Gautam Borthakur, Hagop M. Kantarjian, Jorge E. Cortes, Jan A. Burger

Publikováno v: Blood. 114(10)

Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1f2bb65f4bc2d93e75636d5d8d4381
https://pubmed.ncbi.nlm.nih.gov/19567878

Zobrazit plný text záznamu

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

Autor: Guillermo Garcia-Manero, Sherry Pierce, Stefan Faderl, Michael J. Keating, Charles A. Koller, Susan O'Brien, Deborah A. Thomas, Yang Huh, William G. Wierda, Jeffrey L. Jorgensen, Srdan Verstovsek, Hagop M. Kantarjian, Jorge E. Cortes

Immunophenotypic classification of acute lymphoblastic leukemia (ALL) has well-recognized prognostic implications. The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results. We retrospectivel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c870f683c1abbf5b1cb82bc28dab583e
https://europepmc.org/articles/PMC2943753/

Zobrazit plný text záznamu

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

Autor: Elihu H. Estey, Guillermo Garcia-Manero, Alessandra Ferrajoli, Hagop M Kantarjian, Stefan Faderl, Razelle Kurzrock, Miloslav Beran, Susan O'Brien, Deborah A. Thomas, John J. Wright, Jorge E. Cortes, Stephen A. Bai, Charles A. Koller, Francis J. Giles

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(12)

Purpose To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS). Patients and Methods Pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a87c9e50ebe7004c3a16604a1273e1f
https://pubmed.ncbi.nlm.nih.gov/15728224

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání